Chemical Biology & Drug Design · 2019 · 14 citations · 32 references
PharmacyMedicinal ChemistryPharmacologyCancer PharmacologyDrug DesignOrganic ChemistryHeterocyclic ChemistryLead Compound DesignAnticancer ActivityAnticancer ChemotherapyMedicinal Chemistry ApplicationsMedicinal HeterocyclesPyrimidine Chemistry
Abstract Novel thiourea ( 5a , 5b ) and thiazolidinone derivatives ( 6a , 6b ) were synthesized by hybridizing molecules starting from the compound 6‐(4‐phenylpiperazin‐1‐yl)pyridin‐3‐amine ( 4 ) which is known to show anticancer activity. The synthesis of the leading compound was carried out by using 1‐(5‐nitropyridin‐2‐yl)‐4‐phenylpiperazine ( 3 ) which was obtained by a novel method of the reaction of 2‐chloro‐5‐nitropyridine ( 1 ) and N ‐phenylpiperazine ( 2 ). The structures of the compounds were confirmed using FTIR , 1 H NMR , 13 C NMR , HRMS spectroscopic methods and elemental analysis. The organic molecules were tested for their anticancer activities against prostate cancer (PC) cell lines: DU 145, PC ‐3 and LNC aP. As the compound 5a exerted the highest cytotoxic activity, IC 50 concentrations of compound 5a were further investigated in terms of morphology, colony‐forming ability, RNA expression, fragmented DNA and cell cycle distributions of PC cell lines. Overall data revealed that compound 5a treatment induces apoptosis and DNA fragmentation in PC cell lines and inhibits cell cycle progression resulting in the accumulation of cells in either the G1 or the S phases.
32
Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2019 · 21K citations · Full text
Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2016 · 16.2K citations · Full text
Rate-Limited Steps of Human Oral Absorption and QSAR Studies
Yuan H. Zhao, Michael H. Abraham, Joelle Le et al. · Pharmaceutical Research · 2002 · 707 citations
Chris Gregory, Bin He, Raymond T. Johnson et al. · PubMed · 2001 · 608 citations